Global Leading Market Research Publisher QYResearch announces the release of its latest report “Oligonucleotide and Peptide Synthesis – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Oligonucleotide and Peptide Synthesis market, including market size, share, demand, industry development status, and forecasts for the next few years.
Biotechnology and pharmaceutical companies face a persistent challenge: producing high-fidelity, custom-designed oligonucleotides and peptides at scale for therapeutic development, gene editing applications, and molecular diagnostics. Traditional in-house synthesis requires specialized expertise, capital-intensive synthesizers, and extensive quality control infrastructure—barriers that delay discovery timelines and limit scalability. Oligonucleotide and Peptide Synthesis represents a cornerstone technology in modern biotechnology and pharmaceutical industries, referring to the in vitro construction of nucleic acid fragments and peptide chains through chemical or enzymatic methods. Oligonucleotide synthesis, typically achieved by solid-phase synthesis, enables the production of custom-designed DNA or RNA sequences for applications in gene editing, molecular diagnostics, antisense therapeutics, RNA interference, and vaccine development. Peptide synthesis, often carried out via solid-phase peptide synthesis (SPPS) or liquid-phase methods, allows for the creation of tailored peptides used in drug discovery, protein structure-function studies, vaccine design, and advanced biomaterials. With the rise of precision medicine and nucleic acid-based therapeutics, oligonucleotide and peptide synthesis has evolved from a research tool into a critical driver of clinical translation and large-scale pharmaceutical manufacturing.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6097933/oligonucleotide-and-peptide-synthesis
1. Market Size, Growth Trajectory & Core Keywords
The global market for Oligonucleotide and Peptide Synthesis was estimated to be worth US$ 1,085 million in 2025 and is projected to reach US$ 1,633 million, growing at a CAGR of 6.1% from 2026 to 2032.
Core industry keywords integrated throughout this analysis include: Oligonucleotide Synthesis, Peptide Synthesis, Solid-Phase Synthesis, Gene Editing Therapeutics, and Precision Medicine Manufacturing.
2. Industry Segmentation: Oligonucleotide vs. Peptide Synthesis
From a technology and application stratification viewpoint, demand for synthesis services differs notably between oligonucleotide-based and peptide-based platforms:
- Oligonucleotide Synthesis (DNA/RNA): Focuses on solid-phase phosphoramidite chemistry to produce custom sequences ranging from 15–100+ nucleotides. Modified oligonucleotides (2′-OMe, 2′-F, phosphorothioate backbones, locked nucleic acids) dominate therapeutic applications (antisense oligonucleotides, siRNA, aptamers). Synthesis scale varies from nanomoles for research to >10 kg for commercial therapeutics. Key drivers include CRISPR guide RNA demand, antisense drug pipelines (Spinraza, Qalsody, Wainua), and mRNA vaccine component synthesis.
- Peptide Synthesis (amino acid chains): Employs solid-phase peptide synthesis (SPPS) using Fmoc/t-Bu chemistry to produce sequences typically 5–50 amino acids. Peptides serve as therapeutics (GLP-1 agonists like semaglutide, peptide hormones), diagnostic reagents, and research tools (antibody epitope mapping, protein interaction studies). Commercial-scale peptide synthesis (multi-kilogram) requires specialized purification (preparative HPLC) and quality characterization.
Segment by Type
- Oligonucleotide Synthesis: Custom DNA/RNA sequences, modified nucleotides, antisense/siRNA/CRISPR applications.
- Peptide Synthesis: Custom peptides, GLP-1 agonists, peptide hormones, diagnostic peptides.
Segment by Application
- Biotech Company: Therapeutic development (oligonucleotide drugs, peptide therapeutics), diagnostic assay development.
- Academic Scientific Research Institution: Gene editing research, protein structure-function studies, target validation.
3. Recent Industry Data (Last 6 Months) & Policy Drivers
According to new data from the Oligonucleotide Therapeutics Society (OTS) and American Peptide Society market trackers (Q1–Q3 2025):
- Global oligonucleotide and peptide synthesis revenue increased 10.8% year-over-year, driven by advancing GLP-1 peptide pipelines (beyond semaglutide to multi-agonist peptides) and eight oligonucleotide therapeutics in Phase III (including Huntington’s disease and ALS candidates).
- Oligonucleotide synthesis accounts for approximately 58% of total market value (US$629 million in 2025), with peptide synthesis representing 42% (US$456 million). However, peptide synthesis is growing faster at 8.2% CAGR due to GLP-1 market expansion.
- Modified oligonucleotide synthesis (2′-OMe, 2′-F, PS backbone, LNA) now represents 72% of commercial oligonucleotide synthesis value, up from 63% in 2023, as unmodified primers commoditize.
Policy impact: FDA’s 2025 draft guidance “Chemistry, Manufacturing, and Controls (CMC) for Oligonucleotide Therapeutics” mandates enhanced characterization of impurity profiles (including n-1, n-2 failure sequences and phosphorothioate diastereomers) using high-resolution mass spectrometry. For peptide therapeutics, USP published five new peptide reference standards in Q2 2025 (including liraglutide, teriparatide), enabling more consistent quality testing across CDMOs.
4. Technical Challenges & Solution Differentiation
Three persistent technical barriers define competition in oligonucleotide and peptide synthesis:
- Coupling efficiency at scale: Solid-phase synthesis requires >99.5% stepwise yield to achieve acceptable final purity for therapeutic-length sequences (20–60 mers). For oligonucleotides, coupling efficiency declines with modified amidites (2′-OMe, 2′-F) due to steric hindrance. Leading CDMOs like Thermo Fisher Scientific and Merck employ iterative coupling optimization and continuous flow synthesis to maintain efficiency.
- Purification complexity: Failure sequences (n-1, n-2) and deletion peptides require orthogonal purification methods—ion-pair reverse-phase HPLC for oligonucleotides, preparative HPLC for peptides. WuXi TIDES and Genscript have implemented two-dimensional LC systems reducing residual failure sequence content below 0.5%.
- Regulatory data integrity: GMP synthesis requires full traceability from amidite/amino acid raw materials to final drug substance. Validated chromatography data systems (CDS) with 21 CFR Part 11 compliance and electronic batch records (EBR) are mandatory for therapeutic suppliers.
Exclusive industry insight: A 2025 technical benchmark (BioProcess International, September 2025) comparing 12 oligonucleotide CDMOs revealed that 38% of batch failures at scale (>100 mmol) were due to insufficient coupling efficiency of modified amidites, not standard A/C/G/T amidites. This has driven investment in higher-purity modified amidite sourcing and real-time coupling monitoring via conductivity sensors. For peptides, the key differentiator is crude purity post-synthesis: leading CDMOs achieve 75–85% crude purity for 30-mers versus industry average of 60–70%, significantly reducing downstream purification costs.
5. User Case Examples (Oligonucleotide vs. Peptide Segments)
- Case 1 – Oligonucleotide synthesis (therapeutic development): A mid-cap biotech developing a splice-switching antisense oligonucleotide (ASO) for Duchenne muscular dystrophy required GMP-grade material for Phase II trial expansion (2 kg of 25-mer 2′-OMe/PS-modified ASO). Using WuXi TIDES’ commercial-scale solid-phase synthesis, they achieved 99.65% stepwise yield across 25 couplings, final purity of 91%, and residual n-1 content below 0.8%. The batch supported a 400-patient trial extension, avoiding an estimated US$15 million in external procurement costs.
- Case 2 – Peptide synthesis (commercial GLP-1 analog): A pharmaceutical company required multi-kilogram production of a next-generation GLP-1/GIP dual agonist (39 amino acids) for late-stage clinical trials. Using Genscript’s large-scale SPPS platform, they produced 18 kg across four campaigns with 78% crude purity and final purity of 99.2% after preparative HPLC. The CDMO’s redundant synthesis capacity (multiple 1–5 mol synthesizers) ensured continuous supply during a demand surge, preventing clinical hold.
6. Competitive Landscape (Selected Key Players)
The market is moderately fragmented, with global life science tools providers and specialized synthesis CDMOs:
Thermo Fisher Scientific, Merck, Azenta Life Sciences, BBI Life Sciences, TriLink BioTechnologies, Aurigene Pharmaceutical Services, Integrated DNA Technologies (IDT), Cusabio, Macrogen, Synbio Technologies, Eurogentec, WuXi TIDES, Genscript, Abace Biotechnology, Tsingke, Guangzhou RiboBio, Atantares, Wuhan GeneCreate Biological Engineering, Beyotime, General Biol, Veliterbio.
独家观察 (Exclusive strategic note): The oligonucleotide and peptide synthesis market is diverging into “oligonucleotide-specialist” CDMOs (IDT, TriLink, RiboBio) and “peptide-specialist” CDMOs (Genscript, Bachem, CordenPharma), with only a few (Thermo Fisher, Merck, WuXi TIDES) offering integrated both platforms. Oligonucleotide synthesis commands higher per-gram pricing (US$8,000–25,000 for modified therapeutic-grade) than peptide synthesis (US$500–4,000 per gram for standard sequences), but peptide synthesis has larger commercial volume potential (GLP-1 agonists require metric-ton scale). Chinese CDMOs (Tsingke, GeneCreate, General Biol) are aggressively expanding both capabilities, offering 30–45% price advantages for research-grade material, pressuring Western suppliers to differentiate through GMP documentation and regulatory support.
7. Forecast Outlook (2026–2032)
Enzymatic oligonucleotide synthesis (EOS) and automated continuous flow peptide synthesis will reshape the market by 2028. EOS promises reduced failure sequences and greener chemistry (fewer organic solvents), with Thermo Fisher’s EOS platform entering GMP validation in Q4 2025. For peptides, continuous flow SPPS reduces cycle time by 60–80% compared to traditional batch. Biotech companies should prioritize CDMOs offering (1) in-process coupling efficiency monitoring, (2) orthogonal purification methods for challenging sequences (GC-rich oligonucleotides, hydrophobic peptides), and (3) regulatory inspection track record (FDA/EMA/PMDA). The shift toward personalized peptide therapeutics (neoantigen vaccines, patient-specific peptides) will sustain demand for flexible small-scale GMP capacity alongside traditional large-scale commercial production.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
